• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 17th May 2016

OHE at ISPOR Italy Chapter – Rome: Are Wider Societal Effects Considered in Healthcare Decision-making?

Martina Garau presented at the last ISPOR Italy Chapter – Rome conference on the topic of economic gains produced by health interventions. On 12th April 2016, OHE’s Martina Garau  presented at the ISPOR Italy Chapter – Rome conference on the…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Martina Garau presented at the last ISPOR Italy Chapter – Rome conference on the topic of economic gains produced by health interventions.

On 12th April 2016, OHE’s Martina Garau  presented at the ISPOR Italy Chapter – Rome conference on the topic of the inclusion of wider societal effects in public investment decision making in Italy.

A key example of a wider societal impact is indirect costs, which can arise from reductions in productivity at work or increases in sickness absence, non-employment or early retirement.

Based on evidence from a recently published paper, Martina showed that the inclusion of wider effects in Health Technology Assessment (HTA) decision making processes is still controversial and infrequent.

She concluded that HTA agencies should signal a willingness to consider wider effects systematically, or should initiate pilots to test the appropriateness of selected methods for estimating those effects and the feasibility of incorporating them in decision making. These actions would encourage manufacturers to invest in generating the evidence required to demonstrate the existence and the magnitude of wider effects of specific treatments.

Are Wider Societal Effects Considered in Healthcare Decision-making? An overview from other countries from Office of Health Economics

There were three further presentations at the conference given by:

  • Professor Francesco Saverio Mennini, President of the ISPOR Italy Chapter – Rome;
  • Pierluigi Russo, Director of the HTA Office at the Italian Medicine Agency (AIFA);
  • Giovanna Scroccaro, representative of a regional payer and member of the AIFA Committee.

Professor Francesco Saverio Mennini presented evidence showing the magnitude of indirect costs in some disease areas. For example, in Italy, indirect costs of Hepatitis C, including loss of productivity, total around 600 million of euros (accounting for 60% of the disease total costs); indirect costs of diabetes, including absenteeism and early retirement are estimated to be around 11 billion of euros (accounting for 54% of the disease total costs).

Professor Mennini concluded that this evidence reinforces the need for taking indirect costs into account when allocating resources. In particular, he emphasised the need to identify innovative approaches to tackle the issue of budget silos and to plan resources allocation in an integrated fashion. Money transfers across government departments based on estimated or actual cost savings are a potential way forward.

Pierluigi Russo explained that the AIFA is developing a new guide for manuafactuers, which includes a section on indirect costs. However, the extent to which those costs will be taken into account when making pricing and reimbursement decisions remains to be seen.

Giovanna Scroccaro highlighted that there is a lack of consensus on the most appropriate method(s) of measuring indirect costs. This hinders widespread consideration of such costs in resource allocation decisions. This is also the case for some direct costs, such as hospital admissions, where actual cost savings can be hard to measure and are sometimes overestimated.

For further information please contact Martina Garau  at OHE.

Related work:

Garau, M., Shah, K.K., Sharma, P. and Towse, A., 2016. Is the Link Between Health and Wealth Considered in Decision Making? Results from a Qualitative Study.  International Journal of Technology Assessment in Health Care, 31(6), pp.449-456.

Johannesson, M., Jonsson, B., Jonsson, L., Kobelt, G. and Zethraeus, N., 2009. Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?  OHE Briefing. London: Office of Health Economics.

  • Health Care Systems
  • Presentations

Related News

IRA-course-graphic-for-website-news-FINAL-1
  • News
  • May 2023

New free educational program launched – Explaining the U.S. Inflation Reduction Act

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • June 2020

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!